xml version="1.0" ? wmt-20210204

Walmart Inc.00001041692/4/2021false00001041692021-02-042021-02-040000104169wmt:CommonStockparvalue0.10pershareMember2021-02-042021-02-040000104169wmt:A1.900NotesDue2022Member2021-02-042021-02-040000104169wmt:A2.550NotesDue2026Member2021-02-042021-02-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

________________________

FORM 8-K 

CURRENT REPORT

PURSUANT TO SECTION 13 or 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (date of earliest event reported)

February 5, 2021 (February 4, 2021)

Walmart Inc.

(Exact name of registrant as specified in its charter)

[DATA_TABLE_REMOVED]

702 S.W. 8th Street 

Bentonville, AR 72716-0215 

(Address of Principal Executive Offices) (Zip code)

Registrant's telephone number, including area code

(479) 273-4000 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act: 

[DATA_TABLE_REMOVED]

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

Emerging growth company ☐ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

Today, Walmart Inc. (“Walmart”) issued a statement regarding a dismissal of its lawsuit against the U.S. Department of Justice and the U.S. Drug Enforcement Agency that was filed on October 22, 2020 in federal court in the Eastern District of Texas regarding the roles and responsibilities of pharmacists and pharmacies under the Controlled Substances Act. A copy of the statement is furnished as Exhibit 99.1 to this report. 

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise be subject to the liability of that section and shall not be incorporated by reference into any filing or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing or document.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1Statement by Walmart Inc. with respect to the Lawsuit filed against the U.S. Department of Justice and the U.S. Drug Enforcement Agency (DEA) on October 22, 2020 in the Eastern District of Texas.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 5, 2021

[DATA_TABLE_REMOVED]